Kardigan is a clinical-stage precision therapeutics company focused on developing first-in-class medicines that target the fundamental root causes of specific cardiovascular diseases.

Kardigan leverages deep domain expertise in cardiovascular biology, patient data, and advanced analytics to progress a portfolio of three mid-to-late-stage drug programs including a cardiac myosin activator currently in Phase 2b/3 testing for genetic dilated cardiomyopathy (DCM), a Ph2 asset for calcific aortic valve stenosis (CAVS), and third Ph2 program for acute severe hypertension (ASH). By matching critical disease drivers with targeted treatments, Kardigan aims to move beyond standard symptom management toward functional cures.